Short answer
Trevi Therapeutics, Inc. (TRVI) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$21M
- −81.8% YoY · −20.5% QoQ
- EPS (diluted)
- −$0.13
- −62.5% YoY · −8.3% QoQ
Source: XBRL data from the Trevi Therapeutics, Inc. (TRVI) Q3 2026 10-Q on SEC EDGAR. USD.
Trevi Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, reflecting no product sales since inception
- Net loss $21.5M vs $11.8M YoY, operating loss $24.5M vs $13.9M
- R&D expense $19.1M vs $10.1M, driven by OCEAN-1, LAKE and OCEAN-2 trials
- Cash, equivalents and marketable securities $299.4M; operating cash use $53.8M
- April offering net proceeds $162.3M; additional funding needed for development and commercialization
Risk Factors
- No material risk-factor changes disclosed from the 2025 Form 10-K
- Clinical development risk: Haduvio remains investigational, with clinical trial outcomes determining advancement
- Operational risk: outsourced CRO and manufacturing arrangements may require termination-cost payments
- Supply-chain risk: Par Health supplied approximately $2.5 million of active pharmaceutical ingredient during the quarter
- Financial risk: marketable securities totaled $271.559 million, including $1.502 million of unrealized losses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Trevi Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.